AstraZeneca Aims to Speed Up Amyloidosis Diagnosis
Pharmaceutical company AstraZeneca has launched a global program to halve the diagnosis time for amyloidosis by 2028 and double diagnosis rates for certain forms by 2030.
AstraZeneca has launched the global Accelerate Change Together (ACT) on Amyloidosis program, aiming to significantly improve the diagnosis and treatment of amyloidosis.
The company intends to halve the time to diagnosis by 2028 and double the diagnosis rates for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a form of amyloidosis that often leads to heart failure, by 2030.
Amyloidosis is a progressive and often debilitating disease with a high mortality rate if left untreated. Patients frequently see multiple doctors before receiving a diagnosis. The overall prevalence of the disease is believed to be underestimated, particularly the ATTR-CM form, leading to frequent misdiagnoses and years of undetected illness.
The program also aims to promote proactive patient identification through new diagnostic tools, including AI-assisted echocardiography, electronic health record algorithms, biomarkers, and genetic testing. AstraZeneca is also working to strengthen and expand care pathways by increasing disease awareness and providing education to healthcare professionals.